Paratek's 2026 NUZYRA Areas of Interest
Paratek supports research in multiple areas for NUZYRA (omadacycline), including but not exclusive to:
- Special Patient Populations
- Pathogens or Resistance Mechanisms of Interest
- Additional Disease States
- Not Included in Current Clinical Studies
- Real World Evidence
- Studies Describing the Use, Efficacy and Safety of Omadacycline
NUZYRA Requests for Drug Product for use in IIR
The following NUZYRA formulations are available:
- 1 tablet – 150 mg
- 1 IV vial – 100 mg
- Omadacycline standard powder
Standard Powder Only Requests
If you are interested in only submitting a request for standard powder and no funding, please send a brief proposal via e-mail that includes the following items (1-3 page maximum) to: MedicalAffairs-Research@ParatekPharma.com.
- Rationale/Background
- Description of the Methodology, to include, but not limited to:
- Testing Procedures
- Description of Isolates. Examples:
- Resistance Mechanisms
- Number of Organisms to be Studied
- Source of the Isolates (i.e., surveillance or banked strains, were they clinical?)
- Study Timeline, Including Start and End Date
- Publication/Presentation Plans
- Primary Investigator’s Name, Address, and Shipping Information for the Standard Powder
- Amount of Standard Powder Being Requested
- Name and Contact Information of the Person who will Handle Contracting*
All standard powder requests will require a Materials Transfer Agreement (MTA).
- You will be notified by a representative from Paratek when your request has been approved or denied.
- As stated above, an MTA will need to be signed by both parties before the supply is shipped. Once this is fully executed the shipment will be requested by Paratek, please give a 2-week turnaround for receiving the shipment after a fully executed MTA.
Paratek’s 2026 NUZYRA IIR Review Meeting Schedule:
- February 24, 2026 (Deadline for Submission, February 10, 2026)
- April 28, 2026 (Deadline for Submission, April 14, 2026)
- June 23, 2026 (Deadline for Submission, June 9, 2026)
- August 25, 2026 (Deadline for Submission, August 11, 2026)
- October 27, 2026 (Deadline for Submission, October 13, 2026)
- December 15, 2026 (Deadline for Submission, December 1, 2026)